Table 3.
Multivariable relative risks* and 95% confidence intervals of breast cancer subtypes by tertiles of plasma measures
| Cases/controls | Tertile of plasma measure | P For Trend | Continuous†‡ | |||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| Folate, ng/mL | <12.7 | 12.7 to 19.6 | ≥19.7 | |||
| Invasive breast cancer | 423/1203 | 1.00 (ref.) | 1.19 (0.87, 1.62) | 1.47(1.09, 2.00) | 0.01 | 1.16(1.02, 1.31) |
| In situ breast cancer | 166/1203 | 1.00 (ref.) | 1.14 (0.75, 1.72) | 0.90 (0.58, 1.39) | 0.56 | 1.00 (0.85, 1.19) |
| ER+/PR+ tumors | 291/1203 | 1.00 (ref.) | 1.32 (0.92, 1.89) | 1.60(1.12, 2.29) | 0.01 | 1.15 (0.99, 1.32) |
| ER+/PR− tumors | 38/1203 | 1.00 (ref.) | 1.03 (0.42, 2.54) | 1.54 (0.65, 3.66) | 0.28 | 1.17(0.82, 1.68) |
| ER−/PR− tumors | 72/1203 | 1.00 (ref.) | 1.08 (0.57, 2.04) | 1.20 (0.63, 2.28) | 0.56 | 1.18 (0.90, 1.55) |
| Luminal A | 190/1203 | 1.00 (ref.) | 1.49 (0.98, 2.29) | 1.58 (1.03, 2.45) | 0.06 | 1.08 (0.91, 1.28) |
| Luminal B | 109/1203 | 1.00 (ref.) | 0.95 (0.54, 1.64) | 1.59 (0.95, 2.67) | 0.04 | 1.23 (0.99, 1.53) |
| Vitamin B12, pg/mL | <338 | 338 to 516 | ≥517 | |||
| Invasive breast cancer | 422/1204 | 1.00 (ref.) | 1.47 (1.09, 1.98) | 1.34(1.00, 1.81) | 0.09 | 1.20(1.07, 1.36) |
| In situ breast cancer | 166/1204 | 1.00 (ref.) | 1.02 (0.66, 1.56) | 1.32 (0.87, 1.99) | 0.16 | 1.20(1.01, 1.42) |
| ER+/PR+ tumors | 291/1204 | 1.00 (ref.) | 1.53 (1.08, 2.17) | 1.39 (0.98, 1.97) | 0.10 | 1.24(1.08, 1.42) |
| ER+/PR− tumors | 37/1204 | 1.00 (ref.) | 2.26 (0.92, 5.57) | 1.49 (0.58, 3.85) | 0.60 | 1.11 (0.78, 1.59) |
| ER−/PR− tumors | 72/1204 | 1.00 (ref.) | 0.98 (0.53, 1.83) | 1.09 (0.60, 1.98) | 0.77 | 1.05 (0.82, 1.35) |
| Luminal A | 190/1204 | 1.00 (ref.) | 1.41 (0.94, 2.10) | 1.03 (0.68, 1.55) | 0.96 | 1.10(0.94, 1.29) |
| Luminal B | 109/1204 | 1.00 (ref.) | 1.68 (0.96, 2.93) | 2.11 (1.24, 3.59) | 0.008 | 1.43 (1.16, 1.77) |
| Pyridoxal 5’-phosphate, pmol/mL | <37.5 | 37.5 to 67.0 | ≥67.1 | |||
| Invasive breast cancer | 423/1207 | 1.00 (ref.) | 0.96 (0.72, 1.29) | 1.01 (0.75, 1.35) | 0.89 | 1.06 (0.94, 1.20) |
| In situ breast cancer | 167/1207 | 1.00 (ref.) | 1.13 (0.74, 1.72) | 1.04 (0.68, 1.61) | 0.99 | 1.09 (0.91, 1.29) |
| ER+/PR+ tumors | 291/1207 | 1.00 (ref.) | 0.98 (0.70, 1.38) | 1.02 (0.72, 1.44) | 0.88 | 1.05 (0.91, 1.21) |
| ER+/PR− tumors | 38/1207 | 1.00 (ref.) | 1.29 (0.55, 3.02) | 1.20 (0.50, 2.85) | 0.79 | 1.24 (0.90, 1.71) |
| ER−/PR− tumors | 72/1207 | 1.00 (ref.) | 0.65 (0.35, 1.21) | 0.84 (0.46, 1.53) | 0.79 | 1.01 (0.78, 1.31) |
| Luminal A | 190/1207 | 1.00 (ref.) | 0.97 (0.65, 1.45) | 0.93 (0.62, 1.40) | 0.75 | 1.11 (0.94, 1.30) |
| Luminal B | 109/1207 | 1.00 (ref.) | 1.04 (0.62, 1.75) | 1.14 (0.68, 1.91) | 0.61 | 1.01 (0.81, 1.25) |
| Homocysteine, nmol/mL | <8.3 | 8.3 to 10.0 | ≥10.1 | |||
| Invasive breast cancer | 423/1199 | 1.00 (ref.) | 0.78 (0.58, 1.04) | 0.88 (0.66, 1.18) | 0.48 | 0.95 (0.84, 1.07) |
| In situ breast cancer | 166/1199 | 1.00 (ref.) | 0.90 (0.59, 1.38) | 1.13 (0.75, 1.69) | 0.50 | 1.01 (0.85, 1.20) |
| ER+/PR+ tumors | 291/1199 | 1.00 (ref.) | 0.65 (0.46, 0.92) | 0.83 (0.59, 1.15) | 0.38 | 0.91 (0.79, 1.05) |
| ER+/PR− tumors | 38/1199 | 1.00 (ref.) | 0.72 (0.33, 1.58) | 0.47 (0.19, 1.14) | 0.10 | 0.78 (0.54, 1.12) |
| ER−/PR− tumors | 72/1199 | 1.00 (ref.) | 1.33 (0.71, 2.51) | 1.36 (0.72, 2.58) | 0.38 | 1.15 (0.89, 1.48) |
| Luminal A | 190/1199 | 1.00 (ref.) | 0.66 (0.44, 1.00) | 0.83 (0.56, 1.24) | 0.49 | 0.86 (0.72, 1.01) |
| Luminal B | 109/1199 | 1.00 (ref.) | 0.78 (0.47, 1.28) | 0.72 (0.43, 1.20) | 0.22 | 0.97 (0.79, 1.19) |
| Cysteine, nmol/mL | <231.4 | 231.4 to 253.8 | ≥253.9 | |||
| Invasive breast cancer | 422/1206 | 1.00 (ref.) | 0.95 (0.70, 1.28) | 1.06 (0.78, 1.43) | 0.68 | 1.01 (0.89, 1.15) |
| In situ breast cancer | 166/1206 | 1.00 (ref.) | 1.04 (0.68, 1.59) | 1.37 (0.90, 2.09) | 0.13 | 1.07 (0.90, 1.27) |
| ER+/PR+ tumors | 291/1206 | 1.00 (ref.) | 0.76 (0.53, 1.08) | 0.96 (0.68, 1.36) | 0.93 | 0.98 (0.84, 1.13) |
| ER+/PR− tumors | 38/1206 | 1.00 (ref.) | 1.41 (0.60, 3.35) | 1.26 (0.51, 3.14) | 0.66 | 1.19(0.83, 1.71) |
| ER−/PR− tumors | 71/1206 | 1.00 (ref.) | 1.13 (0.61, 2.09) | 1.05 (0.55, 2.01) | 0.89 | 0.94 (0.70, 1.26) |
| Luminal A | 190/1206 | 1.00 (ref.) | 0.85 (0.56, 1.29) | 0.92 (0.61, 1.39) | 0.73 | 0.89 (0.74, 1.06) |
| Luminal B | 109/1206 | 1.00 (ref.) | 0.91 (0.55, 1.51) | 0.93 (0.55, 1.57) | 0.80 | 1.07 (0.85, 1.34) |
| Cysteinylglycine, nmol/mL | <219.8 | 219.8 to 272.6 | ≥272.7 | |||
| Invasive breast cancer | 419/1199 | 1.00 (ref.) | 1.17 (0.87, 1.58) | 1.08 (0.80, 1.47) | 0.68 | 1.03 (0.91, 1.17) |
| In situ breast cancer | 162/1199 | 1.00 (ref.) | 1.01 (0.68, 1.51) | 0.77 (0.50, 1.19) | 0.23 | 0.90 (0.76, 1.08) |
| ER+/PR+ tumors | 288/1199 | 1.00 (ref.) | 1.11 (0.79, 1.57) | 1.10(0.78, 1.55) | 0.63 | 1.03 (0.89, 1.19) |
| ER+/PR− tumors | 38/1199 | 1.00 (ref.) | 1.38 (0.55, 3.50) | 1.85 (0.76, 4.54) | 0.17 | 1.45 (1.01, 2.07) |
| ER−/PR− tumors | 72/1199 | 1.00 (ref.) | 1.13 (0.64, 2.00) | 0.56 (0.29, 1.10) | 0.09 | 0.76 (0.59, 1.00) |
| Luminal A | 190/1199 | 1.00 (ref.) | 1.25 (0.83, 1.89) | 1.14 (0.76, 1.73) | 0.60 | 1.02 (0.86, 1.20) |
| Luminal B | 106/1199 | 1.00 (ref.) | 1.17 (0.70, 1.97) | 1.07 (0.63, 1.82) | 0.85 | 1.05 (0.84, 1.31) |
*
Unconditional logistic regression with adjustments for matching factors, age at menarche, parity/age at first birth, history of breast cancer in mother or a sister, history of benign breast disease, height, body mass index at age 18, weight change since 18, and alcohol intake.
†
1 SD increase in natural log transformed plasma measure
‡
All p for heterogeneity >0.05; Comparisons: 1) invasive vs. in situ; 2) ER+/PR+ vs. ER+/PR− vs. ER−/PR− tumors; 3) luminal A vs. luminal B